
By Jenny She [1], Stephen Moore [1], Harrison P. Nguyen, MD, MBA, MPH [1,2] | October 02, 2023
Vitiligo is associated with a host of comorbid autoimmune, ocular and auditory, and dermatologic disorders.1 Thyroid disease is the most prevalent of all autoimmune disorders among patients with vitiligo.2 Age, sex, and race affect the presence of other autoimmune comorbidities including alopecia areata, diabetes mellitus, pernicious anemia, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Addison’s disease, inflammatory bowel disease (IBD), Sjögren’s syndrome, multiple sclerosis, and idiopathic thrombocytopenic purpura.1, 3
A 10-year retrospective study found that 23% of patients with vitiligo had one or more of the following autoimmune disorders: thyroid disease, RA, alopecia areata, IBD, SLE, diabetes mellitus, and psoriasis.4 Sex and age influence the prevalence of comorbidities, with Grave’s disease, Hashimoto’s thyroiditis, atopic dermatitis, RA, SLE, and Sjögren’s syndrome more likely in female patients with vitiligo and psoriasis more likely in male patients. SLE and Sjögren’s syndrome are more common among elderly patients with vitiligo and myasthenia gravis is more common among younger patients.5 Race also affects the types of autoimmune comorbidities present. White patients demonstrated the highest rates of comorbidities, with hypothyroidism most frequently found in White and Hispanic/Latino patients. In contrast, psoriasis was most frequent in Asian patients, and SLE and RA were most frequent in Black patients.4
Of all autoimmune disorders, the connection between thyroid disease (especially hypothyroidism and Grave’s disease)6, 7 and vitiligo is most established. Autoimmune thyroid disease (AITD) occurs in a range between 1.61% to 37% of patients with vitiligo compared to only 1% in the general population,8 and patients with vitiligo have a 2.5-times higher risk of developing AITD than those without vitiligo.9 In fact, AITD may have an increased prevalence (6-15%) even among first-degree relatives of patients with vitiligo.10 Vitiligo duration positively correlates with the risk of AITD and larger (>9%) body surface area involvement.11
Vitiligo relates to ocular abnormalities as there are melanocytes located in the uveal tract and retinal pigment epithelium (RPE).12 In a study of 150 patients with vitiligo, 16% have ocular abnormalities in the uvea and RPE compared to 5% of controls.1 18.4% of patients with vitiligo demonstrated signs of normal tension glaucoma, compared with 0% of controls. Similar to the relationship between vitiligo and ocular abnormalities, audiological abnormalities are also being investigated as there are melanocytes located in the inner ear (scala vestibuli).13 68.8% of patients with vitiligo had sensorineural hearing loss (SNHL) compared to 6.3% of controls in a study with 16 patients with vitiligo and 16 healthy controls.14
Furthermore, psoriasis and atopic dermatitis are dermatologic disorders associated with vitiligo, with the latter showing significantly higher prevalence among pediatric patients and patients with early-onset vitiligo.15 There is a strong link between atopic dermatitis and vitiligo, with a systematic review of 16 studies illustrating a much higher frequency of atopic dermatitis among patients with vitiligo in contrast to controls.15
It is critical that care providers remain conscious of these comorbidities in vitiligo, especially autoimmune thyroid disorders. To improve quality of life for patients with vitiligo, future studies should focus on further elucidating the significance of these associations.